Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (£272m) over five years over Washington's insistence on sensitive biological samples.
This rejection came to light after a government memo from December was disclosed, revealing that President Emmerson Mnangagwa believed the deal was "skewed".
A government spokesperson later clarified that the United States was requesting biological samples for research and commercial gain but was unwilling to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of scaling back our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had furnished over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more talks to secure a agreement agreeable to both sides so the country's vital HIV treatment initiative can proceed.
Wider Context
This rejection comes after a similar case in neighbouring Kenya, where a high court blocked a similar deal with the US following concerns were raised about the safety of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump claimed its spending was "inefficient" and his administration was seeking government-to-government deals to enhance openness and responsibility.
According to reports, 16 African countries have to date agreed to these new health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment through American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information over an extended period, with no corresponding promise of access to any medical innovations – like new medicines or tests – that could result from that provided information," he stated.
"Effectively, our nation would supply the raw materials for medical research with no certainty that the resulting innovations would be accessible to our people should a new disease outbreak emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were upending frameworks already set up through the international health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to manage future pandemics.
"This framework is intended to ensure that when a country contributes its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," he added.
"We encourage further dialogue with our American counterparts on how subsequent co-operation might be designed in a way that respects the sovereignty and dignity of both nations."
Health Experts Reaction
A leading public health body expressed it acknowledged the official position, but urged that talks should continue considering a large portion of the nation's Aids initiatives depended on international support.
"In cases where specific concerns exist, including those involving data governance or implementation frameworks, these can frequently be addressed through detailed discussion and mutually agreed protections," it commented.
The halted deal highlights the ongoing challenges between accepting vital foreign assistance and protecting a country's data in an ever more data-driven world.